Related Experiment Video
Updated: May 8, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study
Angelina S Hwang1, Jacob A Kechter1, Xing Li2
1Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA.
Abstract:
Necrobiosis lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the Jak1/2 inhibitor, ruxolitnib, in the treatment of NL and identify the biomarkers associated with the disease and treatment response. We conducted an open-label, phase 2 study of ruxolitinib in 12 patients with NL. We performed transcriptomic analysis of tissue samples before and after treatment. At week 12, the mean NL lesion score decreased by 58.2% (SD = 28.7%, P = .003). Transcriptomic analysis demonstrated enrichment of type I and type II IFN pathways in baseline disease. Weighted gene coexpression network analysis demonstrated post-treatment changes in IFN pathways with key hub genes IFNG and signal transducer and activator of transcription 1 gene STAT1. Limitations include small sample size and a study group limited to patients with <10% body surface area. In conclusion, ruxolitinib is an effective treatment for NL and targets the key pathogenic mediators of the disease.
Insights
Ruxolitinib effectively treats Necrobiosis lipoidica (NL), a rare skin condition. This Janus kinase (JAK) inhibitor significantly reduced NL lesion scores and targets key disease pathways, offering a promising new therapy.
Area of Science:
- Dermatology
- Immunology
- Genomics
Background:
- Necrobiosis lipoidica (NL) is a rare granulomatous skin disease with limited effective treatment options.
- Understanding the underlying molecular pathways is crucial for developing targeted therapies.
Purpose of the Study:
- To evaluate the efficacy and safety of ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, for treating Necrobiosis lipoidica.
- To identify biomarkers associated with NL pathogenesis and response to ruxolitinib treatment.
Main Methods:
- An open-label, phase 2 study involving 12 patients with Necrobiosis lipoidica.
- Transcriptomic analysis of skin tissue samples before and after treatment with ruxolitinib.
- Weighted gene coexpression network analysis to identify key gene pathways.
Main Results:
- Ruxolitinib treatment led to a significant mean decrease of 58.2% in NL lesion scores by week 12 (P = .003).
- Baseline transcriptomic analysis revealed enrichment of type I and type II interferon (IFN) pathways in NL.
- Post-treatment analysis showed modulation of IFN pathways, highlighting IFNG and STAT1 as key hub genes.
Conclusions:
- Ruxolitinib demonstrates significant efficacy and safety as a treatment for Necrobiosis lipoidica.
- The drug effectively targets key pathogenic mediators, particularly interferon pathways, involved in NL.
- Further research is warranted, considering the study's limitations such as small sample size.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
09:38Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:15Bioavailability Study Design: Healthy Subjects Versus Patients